Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?
No OS Benefit Over Chemotherapy
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
You may also be interested in...
Amidst excitement over the potential of PD-1/PARP inhibitor combos in multiple tumor types, Clovis signs a non-exclusive agreement to test Rubraca with Bristol's Opdivo in ovarian, breast and prostate cancer.
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.